Abstract：
OBJECTIVE: The skeletal effects of metformin monotherapy and in combination with teneligliptin are not well illustrated in patients with T2DM. To address this, we conducted an observational study to evaluate the effect of these oral hypoglycemic agents on bone turnover markers.
METHODS: We recruited patients with T2DM and first-ever prescribed metformin monotherapy or metformin combined with teneligliptin from a tertiary care teaching hospital in New Delhi, North India. Both bone formation and resorption markers, IL-6 and PTD, were estimated along with glycated hemoglobin at baseline and 12 weeks.
RESULTS: In both groups, hbA1c levels decreased significantly from baseline to 12 weeks. In the metformin-treated group, β-CTX, sRANKL, IL-6, and PTD decreased significantly, and no significant changes were observed in P1NP, OC, BAP, or OPG at 12 weeks from baseline. In the metformin + teneligliptin group, BAP, β-CTX, sRANKL, IL-6, and PTD decreased significantly, and no significant changes were observed in P1NP, OC, or OPG after 12 weeks from baseline.
CONCLUSIONS: The positive bone outcome of metformin or teneligliptin was linked to bone resorption rather than bone formation and was independent of changes in HbA1c or PTD. However, these results must be confirmed with well-designed RCTs with more extended follow-up periods.
METHODS: We recruited patients with T2DM and first-ever prescribed metformin monotherapy or metformin combined with teneligliptin from a tertiary care teaching hospital in New Delhi, North India. Both bone formation and resorption markers, IL-6 and PTD, were estimated along with glycated hemoglobin at baseline and 12 weeks.
RESULTS: In both groups, hbA1c levels decreased significantly from baseline to 12 weeks. In the metformin-treated group, β-CTX, sRANKL, IL-6, and PTD decreased significantly, and no significant changes were observed in P1NP, OC, BAP, or OPG at 12 weeks from baseline. In the metformin + teneligliptin group, BAP, β-CTX, sRANKL, IL-6, and PTD decreased significantly, and no significant changes were observed in P1NP, OC, or OPG after 12 weeks from baseline.
CONCLUSIONS: The positive bone outcome of metformin or teneligliptin was linked to bone resorption rather than bone formation and was independent of changes in HbA1c or PTD. However, these results must be confirmed with well-designed RCTs with more extended follow-up periods.
摘要：
目的：二甲双胍单药治疗和与替利格列汀联合治疗对T2DM患者的骨骼作用未得到很好的说明。为了解决这个问题，我们进行了一项观察性研究,以评估这些口服降糖药对骨转换标志物的影响.
方法：我们从新德里三级护理教学医院招募了2型糖尿病患者，并首次使用二甲双胍单药或二甲双胍联合替尼格列汀。北印度。骨形成和吸收标志物，IL-6和PTD,在基线和12周时估计糖化血红蛋白。
结果：在两组中，hbA1c水平从基线到12周显着下降。在二甲双胍治疗组中，β-CTX,sRANKL,IL-6和PTD显著降低,P1NP无明显变化,OT,BAP,或OPG在12周从基线。在二甲双胍+替利格汀组中，BAP,β-CTX,sRANKL,IL-6和PTD显著降低,P1NP无明显变化,OT,或OPG后12周从基线。
结论：二甲双胍或替利格汀的骨转归与骨吸收而非骨形成有关，并且与HbA1c或PTD的变化无关。然而,这些结果必须通过精心设计的RCT和延长的随访期来证实.
方法：我们从新德里三级护理教学医院招募了2型糖尿病患者，并首次使用二甲双胍单药或二甲双胍联合替尼格列汀。北印度。骨形成和吸收标志物，IL-6和PTD,在基线和12周时估计糖化血红蛋白。
结果：在两组中，hbA1c水平从基线到12周显着下降。在二甲双胍治疗组中，β-CTX,sRANKL,IL-6和PTD显著降低,P1NP无明显变化,OT,BAP,或OPG在12周从基线。在二甲双胍+替利格汀组中，BAP,β-CTX,sRANKL,IL-6和PTD显著降低,P1NP无明显变化,OT,或OPG后12周从基线。
结论：二甲双胍或替利格汀的骨转归与骨吸收而非骨形成有关，并且与HbA1c或PTD的变化无关。然而,这些结果必须通过精心设计的RCT和延长的随访期来证实.
